Clinical Trial · NCT03527199

Prostate Cancer Patients With Biochemical Recurrence

Overview

Evaluation of detection rate of 18F-Fluciclovine compared to current standard of care imaging techniques within 30 days of the standard of care imaging study and a 6 month phone follow-up

Sponsor

Samsung Medical Center

Contacts

Medhat M Osman, MD,PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03527199

Drug / Compound

Fluciclovine

Isotope(s):

Target(s):

Amino Acid Transport

Ligand Class: Small Molecules

Eligibility

Inclusion

Documented Biochemical recurrence defined as a positive PSA any time after the initial diagnosis of prostate cancer which at that time required surgical resection or radiation and then had a negative result to a post treatment PSA.
History of Prostate Cancer which required surgical resection or radiation
Patient undergoing standard of care work up pelvic CT or MRI, 99mTc-MDP bone scan, and F18 NaF PET/CT. \-

Exclusion

1\. BCR with negative 99mTc-MDP bone scan but 18F-NaF PET/CT was not able to be done.\-